Skip to content
value.today

Vapotherm

VAPOUnlisted company
$17 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$69 M
For year ending December-2023
Net income
$-58 M
-84.7% margin
SEC filing
Employees
550
As on 2021
value.today research

Vapotherm in brief

Vapotherm is an unlisted company in the Medical Devices industry, based in Exeter, New Hampshire, USA. It was founded in 1999. In the year to December 2023 it had sales of $69 M and a net loss of $58 M. It employs about 550 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Vapotherm

Vapotherm Inc. Is a corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Vapotherm timeline

4 events, 1999–2020
  1. 1999
  2. 🏁
    · approximate
    Founded
  3. 2003
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2018
  6. 🔔
    Initial public offering on NYSE
    Final prospectus filed with the SEC on 15 November 2018; shares registered for exchange trading on 9 November 2018.
  7. 2020
  8. 💰
    Record revenue of $126 million
    FY2020, the highest of the 6 years on record.

Events of Vapotherm from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Vapotherm

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 20 September 2024 (Form 8-K).

Market cap history

$0 M$190 M$380 M$569 M$759 M2020202120222023

World rank over time

▼ down 15,414 places since 2020
2020-01-01: #14494#14,49420202021-01-01: #9516#9,51620212022-01-07: #13176#13,17620222022-12-25: #23791#23,79120222023-07-30: #29908#29,9082023

Rank in USA: #3,007 (Jan 2020) · #2,473 (Jan 2021) · #3,226 (Jan 2022) · #4,586 (Dec 2022) · #5,252 (Jul 2023)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-84.7%
Operating margin
-56.9%
Return on equity
—
Liabilities / assets
171.3%
Revenue growth
+2.8%
R&D / revenue
20.7%
Revenue per employee
$125 K
Profit per employee
$-106 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $42M, net income $-42M$42MFY18Fiscal year ending Dec 2019: revenue $48M, net income $-51M$48MFY19Fiscal year ending Dec 2020: revenue $126M, net income $-52M$126MFY20Fiscal year ending Dec 2021: revenue $113M, net income $-60M$113MFY21Fiscal year ending Dec 2022: revenue $67M, net income $-113M$67MFY22Fiscal year ending Dec 2023: revenue $69M, net income $-58M$69MFY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023$69M+2.8%$-39M$-58M-84.7%
Dec 2022$67M-41.0%$-100M$-113M-169.6%
Dec 2021$113M-9.9%$-57M$-60M-52.8%
Dec 2020$126M+161.4%$-43M$-52M-41.0%
Dec 2019$48M+13.5%$-48M$-51M-106.2%
Dec 2018$42M—$-37M$-42M-100.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-24M$3M$-27M$-9.64—
Dec 2022$-80M$12M$-92M$-33.89—
Dec 2021$-55M$6M$-61M$-2.31—
Dec 2020$-39M$10M$-49M$-2.16—
Dec 2019$-40M$5M$-44M$-2.74—
Dec 2018$-40M$5M$-45M$-14.65—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2023: revenue $18M, net income $-18M$18MMar ’23Three months to Jun 2023: revenue $16M, net income $-15M$16MJun ’23Three months to Sep 2023: revenue $15M, net income $-15M$15MSep ’23Three months to Dec 2023 (from the annual report): revenue $20M, net income $-10M$20MDec ’23Three months to Mar 2024: revenue $19M, net income $-15M$19MMar ’24Three months to Jun 2024: revenue $17M, net income $-14M$17MJun ’24

Latest quarter to Jun 2024: revenue $17M (+5.2% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Vapotherm with the US Securities and Exchange Commission.

Annual results

Revenue
$69 M
Operating income
$-39 M
Net income
$-58 M

For year ending December-2023 · source: SEC filing

Balance sheet

Total assets
$78 M
Total liabilities
$133 M
Total equity
$-55 M

As of December-2023

Insider trading at Vapotherm#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
32
since
Vapotherm: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John LandrySVP & Chief Financial OfficerDisposal to the company-45,511——0Form 4
filed Anthony L. ArnerichDirectorDisposal to the company-9,179——0Form 4
filed Lance A. BerryDirectorDisposal to the company-22,485$2.180$49 K0Form 4
filed Donald J. SpenceDirectorDisposal to the company-9,696$2.180$21 K0Form 4
filed Joseph ArmyPresident and CEO, DirectorDisposal to the company-392,094——0Form 4
filed Dorota McKayVP, Controller and CAODisposal to the company-4,625——0Form 4
filed Mary Beth MoynihanDirectorDisposal to the company-8,352$2.180$18 K0Form 4
filed Lori Lynn KnowlesDirectorDisposal to the company-7,862$2.180$17 K0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vapotherm#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 8-for-1 split ; 14-for-1 split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vapotherm scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 4). Fiscal year 2023.

  • Valuationnot known
  • Growth1 of 6
  • Profitability0 of 4
  • Financial health1 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Vapotherm: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Vapotherm: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue69671131264842
Cost of revenue405060632726
Gross profit281753632117
Research and development14211817138.8
Selling and marketing334660653834
General and administrative192831241811
Operating expenses671181101066954
Operating income−39−100−57−43−48−37
Interest and finance income0.10.10.10.30.90.1
Interest expense and finance costs19122.64.75.13.1
Other non-operating income (expense)——0.0−8.5−3.0−5.2
Income before tax−58−113−60−52−51−42
Income tax0.10.0−0.10−0.10
Net income including minority interests−58−113−60−52−51−42
Net income attributable to shareholders−58−113−60−52−51−42
Earnings per share, basic-9.64-33.89r-2.31-2.16-2.74-14.65
Earnings per share, diluted-9.64-33.89r-2.31-2.16-2.74-14.65
Shares, weighted average (basic)6.03.3r26———
Shares, weighted average (diluted)6.03.3r2624192.9
Balance sheet
Cash and cash equivalents9.716571147258
Receivables119.111238.27.1
Inventory233337209.114
Other current assets3.12.15.25.04.12.7
Current assets46601101629382
Property, plant and equipment242722211513
Right-of-use (leased) assets3.45.87.08.3——
Goodwill0.60.515160.60
Other intangible assets004.45.70.40
Total assets789616021611297
Accounts payable5.12.75.95.03.4r3.1
Current liabilities192043421614
Lease liabilities (non-current)2.95.95.46.8——
Total liabilities133124931025846
Retained earnings−548−490−377−317−265−214
Shareholders' equity−55−28671145452
Total liabilities and equity789616021611297
Shares outstanding6.23.6r26262117
Cash-flow statement
Depreciation and amortization5.05.25.64.83.12.2
Share-based compensation9.6109.86.43.80.5
Cash from operating activities−24−80−55−39−40−40
Capital expenditure−3.0−12−5.9−9.8−4.7−5.2
Acquisitions, net of cash acquired——−1.3−8.4−1.6—
Cash from investing activities−3.0−12−7.2−18−6.3−5.2
Debt issued—99—401132
Debt repaid—−40—−43—−22
Shares issued—1.1—944960
Cash from financing activities21514.41005977
Exchange-rate effect on cash————0.0—
Change in cash−6.0−40−58421332
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Vapotherm#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 5 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 6 · New debt 5 · Unregistered share sale 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 10

Vapotherm: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Directors and officersMaterial agreementNew debt8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Material agreementNew debt8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Material agreementNew debt8-K
Results announced8-K
Delisting noticeMaterial agreementNew debt8-K
Results announced8-K
Restructuring8-K/A

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 20, 2024

Acquisitions and funding#

6 private funding rounds before listing

Private share sales · funding history

Private share sales of Vapotherm
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2018$10 MNo. 6$10 to $50 million7equitySEC
May 2017$20 MNo. 5$10 to $50 million15equitySEC
Oct 2015$15 MNo. 4$10 to $50 million20equitySEC
Mar 2015$20 MNo. 3$10 to $50 million19equitySEC
Feb 2014$24 MNo. 2$10 to $50 million17equitySEC
Mar 2013$26 MNo. 1$10 to $50 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its annual reports since 2010, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Vapotherm#

3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $153 K a year.

Certified, FY2026
3
#1,372 among companies on value.today
Worker positions
3
Median wage offered
$153 K
a year, full-time
Applications filed
3
Vapotherm: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Reliability EngineerBioengineers and Biomedical Engineers1$85 K
Senior Security Operations & Compliance EngineerInformation Security Engineers1$153 K
Sr. Quality DirectorIndustrial Production Managers1$197 K

Where: Mesquite, TX 1 · Roanoke, VA 1 · Burlington, MA 1

Vapotherm: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202633$153 K3
FY202422$120 K2
FY202322$158 K2
FY202022$92 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as VAPOTHERM, INC.

Layoffs at Vapotherm#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2022
Latest
—
2022-04-27
Vapotherm: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022············—
Vapotherm: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Vapotherm compares in Medical Devices

  • Revenue$69 M · higher than 32% of 155
  • Net margin-84.7% · higher than 17% of 144
  • Revenue growth2.8% · higher than 26% of 104

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Vapotherm🇺🇸$17 M—-84.7%+2.8%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Employees:
As on 2021
Profile updated:
Nov 14, 2026

Figures from SEC filing, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vapotherm? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vapotherm's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vapotherm? Suggest a correction